TY - JOUR
T1 - Micro-Engineered Heart Tissues On-Chip with Heterotypic Cell Composition Display Self-Organization and Improved Cardiac Function
AU - Cofiño-Fabres, Carla
AU - Boonen, Tom
AU - Rivera-Arbeláez, José M.
AU - Rijpkema, Minke
AU - Blauw, Lisanne
AU - Rensen, Patrick C.N.
AU - Schwach, Verena
AU - Ribeiro, Marcelo C.
AU - Passier, Robert
N1 - Publisher Copyright:
© 2024 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.
PY - 2024/7/17
Y1 - 2024/7/17
N2 - Advanced in vitro models that recapitulate the structural organization and function of the human heart are highly needed for accurate disease modeling, more predictable drug screening, and safety pharmacology. Conventional 3D Engineered Heart Tissues (EHTs) lack heterotypic cell complexity and culture under flow, whereas microfluidic Heart-on-Chip (HoC) models in general lack the 3D configuration and accurate contractile readouts. In this study, an innovative and user-friendly HoC model is developed to overcome these limitations, by culturing human pluripotent stem cell (hPSC)-derived cardiomyocytes (CMs), endothelial (ECs)- and smooth muscle cells (SMCs), together with human cardiac fibroblasts (FBs), underflow, leading to self-organized miniaturized micro-EHTs (µEHTs) with a CM-EC interface reminiscent of the physiological capillary lining. µEHTs cultured under flow display enhanced contractile performance and conduction velocity. In addition, the presence of the EC layer altered drug responses in µEHT contraction. This observation suggests a potential barrier-like function of ECs, which may affect the availability of drugs to the CMs. These cardiac models with increased physiological complexity, will pave the way to screen for therapeutic targets and predict drug efficacy.
AB - Advanced in vitro models that recapitulate the structural organization and function of the human heart are highly needed for accurate disease modeling, more predictable drug screening, and safety pharmacology. Conventional 3D Engineered Heart Tissues (EHTs) lack heterotypic cell complexity and culture under flow, whereas microfluidic Heart-on-Chip (HoC) models in general lack the 3D configuration and accurate contractile readouts. In this study, an innovative and user-friendly HoC model is developed to overcome these limitations, by culturing human pluripotent stem cell (hPSC)-derived cardiomyocytes (CMs), endothelial (ECs)- and smooth muscle cells (SMCs), together with human cardiac fibroblasts (FBs), underflow, leading to self-organized miniaturized micro-EHTs (µEHTs) with a CM-EC interface reminiscent of the physiological capillary lining. µEHTs cultured under flow display enhanced contractile performance and conduction velocity. In addition, the presence of the EC layer altered drug responses in µEHT contraction. This observation suggests a potential barrier-like function of ECs, which may affect the availability of drugs to the CMs. These cardiac models with increased physiological complexity, will pave the way to screen for therapeutic targets and predict drug efficacy.
KW - UT-Hybrid-D
KW - endothelial cells (ECs)
KW - engineered heart tissues (EHTs)
KW - heart-on-Chip (HoC)
KW - human pluripotent stem cells (hPSC)
KW - microfluidics
KW - cardiomyocytes (CMs)
UR - http://www.scopus.com/inward/record.url?scp=85188052862&partnerID=8YFLogxK
U2 - 10.1002/adhm.202303664
DO - 10.1002/adhm.202303664
M3 - Article
C2 - 38471185
AN - SCOPUS:85188052862
SN - 2192-2640
VL - 13
JO - Advanced healthcare materials
JF - Advanced healthcare materials
IS - 18
M1 - 2303664
ER -